-
Using tropical fish to find treatments for brain disorders
https://braincanada.ca/about/news-updates/using-tropical-fish-to-find-treatments-for-brain-disordersThe traditional target-based drug development strategy (in vitro screening) has had poor success in developing new drugs. The vast majority of Investigational New Drugs (INDs) fail in clinical trials due to toxicity or lack of efficacy. On the other hand, mammalian models are excellent tools to...
-
Using worms to investigate the disease mechanisms of ALS
https://braincanada.ca/about/news-updates/using-worms-to-investigate-the-disease-mechanisms-of-alsThe project Alex Parker and his team are focused on developing and using simple models to study brain diseases, specifically ALS. The model system they use is the Caenorhabditis elegans (C. elegans) worm. This small, transparent worm has just 300 neurons, but is a powerful genetic system used by...
-
Utilizing next generation intersectional approaches to define the roles of POMC neuron subpopulations
https://braincanada.ca/funded-grants/utilizing-next-generation-intersectional-approaches-to-define-the-roles-of-pomc-neuron-subpopulationsThe central nervous system controls numerous processes, including appetite and body weight regulation. Project Overview The central nervous system controls numerous processes, including appetite and body weight regulation. Given the alarming rise in global obesity, understanding how the CNS...
-
Validation of clinical assays to measure GCase activity in white blood cells for identifying GBA1-associated Parkinson’s Disease
https://braincanada.ca/funded-grants/validation-of-clinical-assays-to-measure-gcase-activity-in-white-blood-cells-for-identifying-gba1-associated-parkinson-s-diseaseEnzymes are mother nature’s catalysts responsible for the chemistry of metabolic pathways in living cells. In some diseases, the function of an enzyme is deficient which can lead to dysfunction or early cell death. Project Overview Enzymes are mother nature’s catalysts responsible for the chemistry...
-
Validation of cognitive rehabilitation program adapted to the needs of adults with brain cancer and adult survivors of childhood brain cancer.
https://braincanada.ca/funded-grants/validation-of-cognitive-rehabilitation-program-adapted-to-the-needs-of-adults-with-brain-cancer-and-adult-survivors-of-childhood-brain-cancerWe propose a randomized controlled trial to evaluate the efficacy of Goal Management Training (GMT) for improving these patients’ cognitive functioning as well as patient and caregiver QoL. Project Overview We propose a randomized controlled trial to evaluate the efficacy of Goal Management...
-
Validation of Connexins and Pannexins as a target for Alzheimer’s Disease
https://braincanada.ca/funded-grants/validation-of-connexins-and-pannexins-as-a-target-for-alzheimer-s-diseaseAlzheimer’s Disease (AD) is the most common cause of dementia, accounting for over two thirds of cases. As of 2013, there are over 44 million people with dementia worldwide. Project Overview Alzheimer’s Disease (AD) is the most common cause of dementia, accounting for over two thirds of cases. As...
-
Validation of ocular measures as potential biomarkers for early detection of brain amyloid and neurodegeneration
https://braincanada.ca/funded-grants/validation-of-ocular-measures-as-potential-biomarkers-for-early-detection-of-brain-amyloid-and-neurodegeneration500,000 Canadians have dementia, a number that will double within a generation due to the ongoing aging demographics of the population, with annual costs estimated to increase from $15B currently to over $150B by the year 2050. Project Overview 500,000 Canadians have dementia, a number that will...
-
Validation of small molecules preventing TDP-43 aggregation as a therapeutic for Amyotrophic Lateral Sclerosis
https://braincanada.ca/funded-grants/validation-of-small-molecules-preventing-tdp-43-aggregation-as-a-therapeutic-for-amyotrophic-lateral-sclerosisTDP-43 is a protein that behaves abnormally in the motor neurons of 97 per cent of people with ALS. Project Overview TDP-43 is a protein that behaves abnormally in the motor neurons of 97 per cent of people with ALS. It is usually found in the nucleus, but in people with ALS, it becomes trapped...
-
Vascular innervation and blood-brain barrier dysfunction in Huntington’s disease using human iPSC-derived vascularized brain organoids.
https://braincanada.ca/funded-grants/vascular-innervation-and-blood-brain-barrier-dysfunction-in-huntington-s-disease-using-human-ipsc-derived-vascularized-brain-organoids“Vascular pathology, such as loss of neurovascular coupling and disruption of the blood-brain barrier (BBB), has been documented in Huntington’s disease (HD). Project Overview “Vascular pathology, such as loss of neurovascular coupling and disruption of the blood-brain barrier (BBB), has been...
-
Vascular Interface with the Brain and Neurocognition via the Eyes (VIBE): Retinal Photography in Youth with Psychiatric Disorders
https://braincanada.ca/funded-grants/vascular-interface-with-the-brain-and-neurocognition-via-the-eyes-vibe-retinal-photography-in-youth-with-psychiatric-disordersThe goal of this study is to advance knowledge regarding the association of vascular risk factors and blood vessels with brain structure and function in youth with severe mental illness. Project Overview The goal of this study is to advance knowledge regarding the association of vascular risk...
Skip to main content
